Real-world analysis of teclistamab in 123 RRMM patients from Germany
Real-world analysis of teclistamab in 123 RRMM patients from Germany
About this item
Full title
Author / Creator
Riedhammer, C. , Bassermann, F. , Besemer, B. , Bewarder, M. , Brunner, F. , Carpinteiro, A. , Einsele, H. , Faltin, J. , Frenking, J. , Gezer, D. , Goldman-Mazur, S. , Hänel, M. , Hoegner, M. , Kortuem, K. M. , Krönke, J. , Kull, M. , Leitner, T. , Mann, C. , Mecklenbrauck, R. , Merz, M. , Morgner, A. , Nogai, A. , Raab, M. S. , Teipel, R. , Wäsch, R. and Rasche, L.
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Teclistamab, a B-cell maturation antigen (BCMA) × CD3 directed bispecific antibody, has shown high response rates and durable remissions in the MAJESTEC-1 trial in patients with relapsed and refractory multiple myeloma (RRMM). We retrospectively assessed efficacy and tolerability in 123 patients treated at 18 different German centers to determine w...
Alternative Titles
Full title
Real-world analysis of teclistamab in 123 RRMM patients from Germany
Authors, Artists and Contributors
Author / Creator
Bassermann, F.
Besemer, B.
Bewarder, M.
Brunner, F.
Carpinteiro, A.
Einsele, H.
Faltin, J.
Frenking, J.
Gezer, D.
Goldman-Mazur, S.
Hänel, M.
Hoegner, M.
Kortuem, K. M.
Krönke, J.
Kull, M.
Leitner, T.
Mann, C.
Mecklenbrauck, R.
Merz, M.
Morgner, A.
Nogai, A.
Raab, M. S.
Teipel, R.
Wäsch, R.
Rasche, L.
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10844072
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10844072
Other Identifiers
ISSN
0887-6924
E-ISSN
1476-5551
DOI
10.1038/s41375-024-02154-5
